Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. · 2009

Read Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. by Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2671563.txt.

Description

Björk and co-authors solved in 2009 a 25-year puzzle: what a promising class of immune-calming drugs actually grabs onto in the human body. The drugs, called quinoline-3-carboxamides, were already in mid-stage trials for autoimmune disease, yet their target had stayed hidden. The team tagged one drug with a radioactive label that locks onto whatever it touches under light.

The tag landed on a single protein, S100A9, and only when zinc and calcium were present. That protein, so loaded, switches on two inflammation alarms, the sensors RAGE and TLR4. The drugs block both handshakes. Tweaks to the drug's shape changed its grip on S100A9 and its power in mice with a multiple sclerosis-like illness in step together. The protein also proved necessary for the drugs to cut a key inflammatory signal in living animals.

Catalog record

CREATORBjörk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2671563

Browse the full library · About the Tower of Babel